Generic versions of major hepatitis C virus (HCV) drugs are apparently very effective, MedPage Today reports. Researchers in the REDEMPTION-1 trial gave 448 people with genotype 1 or 3 of hep C generic versions of Harvoni (ledipasvir/sofosbuvir) and the Sovaldi (sofosbuvir) and Daklinza (daclatasvir) regimen.

Interim findings were presented at the 51st International Liver Congress in Barcelona.

A cure for hep C is defined as having a sustained virologic response 12 weeks after completing therapy (SVR12). Those who have an undetectable hep C viral load four weeks after finishing treatment have achieved what is known as an SVR4, which is a very good indicator that they will go on to have an SVR12.

Ninety-five percent of those with genotype 1 achieved an SVR4, as did 90 percent of those with genotype 3.

Such success bodes well for the use of generic hep C medications in poorer nations.

To read the MedPage Today article, click here.